CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial Dual Antiplatelet TherapyIs It Time to Cut the Cord With Aspirin? Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction Long-term dual antiplatelet-induced intestinal injury resulting in translocation of intestinal bacteria into blood circulation increased the incidence of adverse events after PCI in patients with coronary artery disease Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY

Clinical Trial2020 Nov 12;S0140-6736(20)32236-4.

JOURNAL:Lancet. Article Link

Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial

J Silvain, B Lattuca, ALPHEUS investigators et al. Keywords: ticagrelor vs. clopidogrel; periprocedural myocardial necrosis; stable coronary artery disease; aspirin and clopidogrel; intravenous cangrelor;

Full Text PDF